Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 
@ the Bell: Major markets slip, fall & flatten as commodities drop on recession worries
Canada’s resource-heavy main stock index fell on Wednesday as weakness in oil and metal & mining prices weighed on commodity stocks amidst growing fear of a global recession.The energy sector... read article.

RE:$364,xxx

I think it's more like $134,500 because it shows as counted twice. Regardless, it's great to see him continually picking up more shares and I think you're bang on about what he sees as the...read more

Neovasc Announces Direct Sales Operations in United Kingdom

Fred Colen, Neovasc President and Chief Executive Officer, said, “We are pleased to expand our direct presence into the United Kingdom and want to thank our partners at Healthcare 21 for their excellent foundational efforts supporting the early growth of Reducer. We are now poised to provide even deeper support with a full-time dedicated team in the U.K. and intend to continue to invest in clinical research and field personnel to support patients, physicians, and hospitals.” ...read more

$364,xxx

Closer approximation.  Apologies.  rate and reply

$415,000 approximately

is a pretty awesome / sizeable buy-in from the top!  rate and reply

The Gist of whats happening…

An accomplished pharma executive/ capital allocator, multinational entrepreneur seems to really believe what he has created and what the team and he are building upon! he gets to see what is...read more

more buying ...

The data isn't entered properly (as per totals) but you get the gist of what's going on. : ) Filed 2022-07-05 16:57   Tx date 2022-07-04 ...read more
@ the Bell: Commodities drag TSX stocks lower as recession fears grip global markets
Canada’s main stocks index slid more than 1 per cent on Tuesday, following up a bigger market selloff as global recession worries came to the forefront, while energy stocks dipped along with oil... read article.

Goodman sees no reason to stop buying ...

I wish Goodman all the cheap tickets to the game - may he get them all !!!!! Filed 2022-07-04 14:50   Tx date 2021-11-22 $GUD Knight...read more

GUD relaunches AKYNZEO in Brazil

https://themarketherald.ca/knight-therapeutics-announces-relaunch-of-akynzeo-in-brazil-2022-07-04/  rate and reply

GUD getting busy

GUD exposure in US with two conferences in New York on 10th & 14th in San Diego.   continued buys by BOD w Tremblay.  -commitment Drugs in South America launching...read more

New Press Release - Knight Therapeutics announces relaunch of AKYNZEO® in Brazil

MONTREAL, July 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., is assuming full commercial activities and is relaunching AKYNZEO® (netupitant /...read article.

RE:RE:Tremblay on the buy side !

Even a significant buy isn't going to move the needle - that comes from outside investors getting excited.  Re. Exelon - no idea - lost track of the details.  Just waiting for them to...read more

RE:RE:Tremblay on the buy side !

https://www.globenewswire.com/news-release/2022/06/01/2454130/0/en/Knight-Therapeutics-Assumes-Commercial-Activities-for-Exelon-in-Colombia.html Done for this one but I saw nothing for Brazil, did...read more

RE:Tremblay on the buy side !

I would prefer a significant buy Do we know if they got 100 % control of Exelon in Brazil as expected ?  rate and reply

Tremblay on the buy side !

There's a board name you don't see on the buy side too often ... Filed 2022-07-03 11:10   Tx date 2022-06-30 $GUD Knight...read more

RE:RE:RE:Big Pharma has compelling valuations & ‘ROOM to RUN’

It's really a battle between debtors who want to get paid now vs. controlling debtors who want ENDO to miss the present debt payments and focus on overall restructuring. Not exactly sure how you...read more

RE:RE:Big Pharma has compelling valuations & ‘ROOM to RUN’

It would appear that Endo has double-downed on the same hubris that brought it to its present condition. It is shocking for them to say that they do not have a "Liquidity Issue". There...read more

RE:Big Pharma has compelling valuations & ‘ROOM to RUN’

This big pharma may have to raise cash.  Endo crashes 27% after missing interest payment Endo International (NASDAQ:ENDP) dropped ~27% in the pre-market Thursday after the generic...read more
Buzz on the Bullboards: Sizzling sector highlights
It has been a sizzling few days recently for most of North America, both weather-wise and for investing discussions. The markets face a rate hike in the U.S., ongoing inflation, rising oil and... read article.

Big Pharma has compelling valuations & ‘ROOM to RUN’

Commentary on CNBC. & GUD, not Big pharma, just getting started GUD  times ahead. Compelling valuation indeed! GI  rate and reply

RE:Shorts increase

For Years GUD MNGT has tried to stiff the short sellers with buy back, it has not worked   rate and reply

Shorts increase

$GUD.TO KNIGHT THERAPEUTICS INC. 3,745,386 143,225 14 Jun 2022 $GUD.TO KNIGHT THERAPEUTICS INC. 3,602,161 -66,616 30 May...read more

Latin America June 2022 travel restrictions update

https://www.forbes.com/sites/geoffwhitmore/2022/06/02/june-2022-travel-restrictions-update/?sh=727f66c03669 Most countries are fully open or open to vaccinated travellers. more travel, lower Covid...read more